Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

News

17 December 2021

Our 3rd Newsletter is out

Scroll through the QSPainRelief December 2021 Newsletter to learn about the project’s progress, highlights and outcomes of the 3rd GA Meeting, two new Masterclasses, upcoming events, and new team- and SEAB-members. We are also updating you on Bachelor students’ projects conducted for QSPainRelief in Prof. Dr. Liesbeth de Lange’s group at ULEI and clarify that all 2020 registrations for the Quantitative Systems Pharmacology Conference are valid for QSPC2022 – the replacement date next year in Leiden, The Netherlands, from 20 – 22 April 2022.

More news

Events

13-15 December 2021

Successful & motivating 3rd GA Meeting

The 3rd QSPainRelief General Assembly (GA) Meeting took place as a virtual Zoom meeting from 13-15 December 2021. Highlights were the two Masterclasses held by Prof. Dr. Jesús Giraldo and Robert Carr together with Dr. Athan Spiros, a productive Impact and Innovation Board (IIB) meeting, and the early-career scientists’ (ECS) presentations. Despite the pandemic, all work packages (WPs) have been very productive and are doing their best to stay on track. Fun coffee break activities gave us insight into each other’s personalities.

More events
Personalise and maximize pain relief for individuals suffering from chronic pain

Summary Statement

10 institutions in Europe and the USA collaborate for the next 5 years to help patients suffering from chronic pain. QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.

Learn more

Objectives

  • Consolidating cutting-edge treatment models for chronic pain
  • Summary Statement
  • Validating novel combinational therapies preclinically in vitro and in vivo
  • Conducting clinical studies to detect functional biomarkers
  • Improving the clinical guidelines for pain relief in stratified patient groups
  • Personalising pain relief treatment for each patient
  • Improving the scientific understanding of chronic pain regarding age, sex, disease and genetic factors

Impact

  • Novel concepts of combinational pain relief therapies
  • Improved efficacy and acceptability in the clinic
  • Effective stratification of patients with respect to age, sex, disease and genotype
  • Personalised treatment with unswerving benefits for patients
  • Unique knowledge gain and innovation opportunities